The Role of Phorbol Ester Receptor Binding in Responses to Promoters by Mouse and Human Cells

  • N. H. Colburn
  • T. D. Gindhart
  • B. Dalal
  • G. A. Hegamyer
Part of the Basic Life Sciences book series


One of the major unanswered questions in carcinogenesis today concerns the rate-limiting steps that determine premalignant progression during the long latent period from the onset of carcinogen exposure until tumor appearance. Since tumor promoters apparently act to increase both the probability of occurrence and the rate of traversing events leading to malignancy, attempts to counter these promoter-induced events might offer a promising means of cancer prevention. In this connection, an understanding of the basis for resistance to tumor promoters could lead to an exploitable strategy. Our laboratory has developed the JB6 mouse epidermal cell model system for studying late-stage irreversible promotion of transformation by phorbol esters and other tumor promoters. We have recently described the isolation of promotion-resistant variants of JB6 cells which permit us to study the molecular and cellular basis for resistance (1,2). Since phorbol esters bind to specific cellular receptors and since resistance to a variety of hormones that also bind to specific receptors is associated with receptor deficiency (3), we have investigated whether the resistance of phorbol ester-resistant JB6 mouse cells can be attributed to a lack of phorbol diester receptors. This inquiry has been extended to phorbol ester-resistant variants of human hematopoietic cells.


HL60 Cell Phorbol Ester Scatchard Analysis Mitogenic Response Human Hematopoietic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Colburn, N.H., B. Koehler, and K.A. Nelson. 1980. A cell culture assay for tumor promoter dependent progression toward neoplastic phenotype: Detection of tumor promoters and promotion inhibitors. Teratogen. Carcinogen. Mutagen. 1: 87–96.Google Scholar
  2. 2.
    Colburn, N.H., E.J. Wendel, and G. Abruzzo. 1981. Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: Mitogen resistant variants are sensitive to promotion. Proc. Natl. Acad. Sci. USA 78:: 6912–6916.Google Scholar
  3. 3.
    Pollet, R.J., and G.S. Levey. 1980. Principles of membrane receptor physiology and their application to clinical medicine. Ann. Int. Med. 92: 663–680.Google Scholar
  4. 4.
    Lozzio, C.B., and B.B. Lozzio. 1975. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 45: 321–334.PubMedGoogle Scholar
  5. 5.
    Collins, S.J., R.C. Gallo, and R.E. Gallagher. 1977. Continuous growth and differentiation of human myeloid leukemic cells in a suspension culture. Nature (London) 270: 347–349.CrossRefGoogle Scholar
  6. 6.
    Pruss, R.M., and H.R. Herschman. 1977. Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc. Natl. Acad. Sci. USA 74: 3918–3921.Google Scholar
  7. 7.
    Colburn, N.H., W.F. Vorderbruegge, J.R. Bates, R.H. Gray, J.D. Rossen, W.H. Kelsey, and T. Shimada. 1978. Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res. 38: 624–634.PubMedGoogle Scholar
  8. 8.
    Colburn, N.H., B.F. Former, K.A. Nelson, and S.H. Yuspa. 1979. Tumor promoter induces anchorage independence irreversibly. Nature 281: 589–591.PubMedCrossRefGoogle Scholar
  9. 9.
    Knott, G.D., and D.K. Reece. 1972. M-LAB: A civilized curve-fitting system. Proc. Int. Conf. on Online Interactive Computing, Vol 1. Online Computer Systems, Oxbridge, England. pp. 497–526.Google Scholar
  10. 10.
    Solanki, T.J., M. Slaga, R. Callahan, and E. Huberman. 1981. Down regulation of specific binding of [20–3H]phorbol 12,13-dibutyrate and phorbol ester induced differentiation of human promyelocytic leukemia cells. Proc. Natl. Acad. Sci. USA 78: 1722–1725.Google Scholar
  11. 11.
    Colburn, N.H., T.D. Gindhart, G.A. Hegamyer, P.M. Blumberg, B. Delclos, B.E. Magun, and J. Lockyer. (in press). The role of phorbol diester and EGF receptors in determining sensitivity to TPA. Cancer Res.Google Scholar
  12. 12.
    Driedger, P.E., and P.M. Blumberg. 1980. Specific binding of phorbol ester tumor promoters. Proc. Natl. Acad. Sci. USA 77: 567–571.Google Scholar
  13. 13.
    Dunphy, W.G., K.B. Delclos, and P.M. Blumberg. 1980. Characterization of specific binding of [3H]phorbol 12,13-dibutyrate and [3H]phorbol-12-myristate 13-acetate to mouse brain. Cancer Res. 40: 3635–3641.PubMedGoogle Scholar
  14. 14.
    Delclos, K.B., D.S. Nagle, and P.M. Blumberg. 1980. Specific binding of phorbol ester tumor promoters to mouse skin. Cell 19: 1025–1032.PubMedCrossRefGoogle Scholar
  15. 15.
    Fisher, P.B., H. Cogan, A.D. Horowitz, D. Schachter, and I.B. Weinstein. 1981. TPA resistance in Friend erythroleukemia cells: Role of membrane lipid fluidity. Biochem. Biophys. Res. Comm. 100: 370–376.Google Scholar
  16. 16.
    Mendelsohn, N., H.S. Gilbert, J.K. Christman, and G. Acs. 1980. Effect of maturation on the response of human promyelocytic leukemia cells (HL-60) to the tumor promoter 12–0-tetradecanoylphorbol-13-acetate. Cancer Res. 40: 1469–1474.PubMedGoogle Scholar
  17. 17.
    Horowitz, A.D., E. Greenbaum, and I.B. Weinstein. 1981. Identification of receptors for phorbol ester tumor promoters in intact mammalian cells and of an inhibitor of receptor binding in biologic fluids. Proc. Natl. Acad. Sci. USA 78: 2315–2319.Google Scholar
  18. 18.
    Seaman, W.S., T.D. Gindhart, M.A. Blackman, B. Dalal, N. Talal, and Z. Werb. 1981. Natural killing of tumor cells by human peripheral blood cells: Suppression of killing in vitro by tumor promoting phorbol diesters. J. Clin. Invest. 67: 1324–1333.Google Scholar
  19. 19.
    Kensler, J.W., and M.A. Trush. 1981. Inhibition of phorbol ester-stimulated chemiluminescence in human polymorphonuclear leukocytes by retinoic acid and 5,6-epoxyretinoic acid. Cancer Res. 41: 216–222.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • N. H. Colburn
    • 1
  • T. D. Gindhart
    • 2
  • B. Dalal
    • 2
  • G. A. Hegamyer
    • 1
  1. 1.Laboratory of Viral CarcinogenesisNational Cancer InstituteFrederickUSA
  2. 2.Laboratory of Chemical PharmacologyNational Cancer InstituteBethesdaUSA

Personalised recommendations